[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-endometrioid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-endometrioid":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100552063","fertility-sparing-therapy-for-patients-with-stage-ia-g2-endometrial-cancer-100552063",false,"NCT06468215","Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer","Inclusion Criteria:\n\n* Endometrioid adenocarcinoma G2, diagnosis by pathological.\n* The lesion is limited to the endometrium.\n* FIGO (2009) staging is IA.\n* Age less than 45.\n* Strongly request to preserve fertility.\n* Sign informed consent.\n\nExclusion Criteria:\n\n* The tumor has invaded the muscle layer.\n* FIGO (2009) stage IB or higher.\n* Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer\n* There are malignant tumors in other systems.\n* Have contraindications for conservative treatment or drug use.\n* Have been judged by the researcher to be unsuitable for childbearing.","FEMALE","45 Years",{"count":18,"type":19},16,"ESTIMATED","INTERVENTIONAL",[22],"NA","Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.",[25,26],"Carcinoma, Endometrioid","Fertility Preservation",[28,29,30],"endometrial cancer","fertility-sparing treatment","grade 2","NOT_YET_RECRUITING","2024-07-13",{"date":34,"type":35},"2024-07-16","ACTUAL",{"date":37,"type":19},"2024-07",{"date":39,"type":19},"2028-10",{"name":41,"class":42},"Peking University People's Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":16,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100511896","fertility-sparing-therapy-for-patients-with-stage-ia-endometrial-cancer-100511896","NCT05945407","Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","Establishment of a Network Platform for Fertility-sparing in Patients With Endometrial Cancer and Study on Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer.","Inclusion Criteria:\n\n* Stage IA (FIGO 2009) ;\n* Pathological diagnosis: endometrial adenocarcinoma G1-G2;\n* MRI or ultrasound: tumor limited to endometrium or invading less than 1\u002F2 of myometrium；\n* 18 years old ≤ Age ≤ 45 years old;\n* With a strong desire for fertility preservation；\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Complicated with any other malignancy；\n* Contraindications to conservative treatment；\n* Contraindications to progestin use;\n* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.","18 Years",{"count":52,"type":19},57,[22],"The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1\u002F2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.",[56,57,58,25,26],"Endometrial Neoplasms","Endometrial Neoplasm Malignant","Endometrial Neoplasm Malignant Stage I",[60,61,62,63,64],"Fertility-sparing","Fertility-preserving","Endometrial Carcinoma","Endometrial Cancer","Indication Extension","RECRUITING","2023-07-12",{"date":68,"type":35},"2023-07-14",{"date":70,"type":35},"2016-08-01",{"date":72,"type":19},"2027-12-31",{"name":41,"class":42},1]